RIRodney Elwood Infante

Rodney Elwood Infante

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rodney Elwood Infante has a total of 98 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Targeting pseudokinases: A STRADegy for tumor-suppressor activation

    byĀ Rodney E. Infante, John D. Minna

  • Top Cited Papers
    Open Access

    Cancer cachexia in STK11/LKB1-mutated non-small cell lung cancer is dependent on tumor-secreted GDF15

    byĀ Jinhai Yu, Tong Guo, Arun Gupta, Ernesto M. Llano, Thomas Salisbury, Naureen Wajahat, Dianne Zhao, Sean Slater, Qing Deng, Esra A. Akbay, et al.

    Cachexia is a wasting syndrome involving adipose, muscle, and body weight loss in cancer patients. Tumor loss-of-function mutations in STK11 / LKB1 , a regulator of AMP-activated protein kinase, induce cancer cachexia (CC) in preclinical models and are linked to weight loss in non-small cell lung cancer (NSCLC) patients. This study examines the role of the integrated stress response (ISR) cytokine growth differentiation factor 15 (GDF15) in regulating cachexia using patient-derived and engineered STK11/LKB1 -mutant NSCLC lines. Tumor cell-derived serum GDF15 levels are elevated in mice bearing these tumors. Treatment with a GDF15-neutralizing antibody or silencing GDF15 from tumor cells prevents adipose/muscle loss, strength decline, and weight reduction, identifying tumors cells as the GDF15 source. Restoring wild-type STK11/LKB1 in NSCLC lines with endogenous STK11/LKB1 loss reverses the ISR and reduces GDF15 expression rescuing the cachexia phenotype. Collectively, these findings implicate tumor-derived GDF15 as a key mediator and therapeutic target in STK11/LKB1 -mutant NSCLC-associated cachexia.


  • Open Access

    Targeting the GDF15-GFRAL pathway in NSCLC cachexia: from stress responses to targeted therapies

    byĀ Jinhai Yu, Xiaotong Zhu, Tong Guo, Arun Gupta, Naureen Wajahat, Natalie Lopez, Andrey Popugailo, Puneeth Iyengar, Rodney E. Infante

  • Open Access

    Undetected Weight Loss Associates With Upstaging in Cancer Patients

    byĀ L. Anne Gilmore, Evie Y. Dunsky, A. Jacob Miller, Christian M. Alvarez, Santiago Olaechea, Brian W. Gilmore, Chul Ahn, Puneeth Iyengar, Rodney E. Infante

    Background: Unintentional weight loss (UWL) is the primary diagnostic parameter for cancer cachexia in the clinic. Prompt identification of UWL can lead to earlier diagnoses and interventions for cancer. This study investigates the frequency and timing of UWL documentation and diagnoses in a cohort of cancer patients with measured UWL and sought to understand how recognition of UWL is related to stage of disease at cancer diagnosis. Methods: A retrospective cohort of adult gastrointestinal and non‐small cell lung cancer patients with measured UWL was evaluated. Body weight histories were manually reviewed for UWL. Patients with intentional weight loss, weight loss related to fluid status or weight loss with unclear intention were excluded. Records were assessed for the use of UWL‐related International Classification of Diseases codes and documentation of UWL. ULW was considered missed if it was not documented or diagnosed by a healthcare provider. Associations between weight loss over time, documentation and/or diagnosis of UWL and stage of disease at cancer diagnosis were investigated through repeated measures mixed models and univariate and multivariate tests. Results: In total, 374 patients (24%) met the definition of UWL with an average weight loss of 8.6% ± 0.3%. UWL was missed in 161 (43%) patients with cancer cachexia. The odds of undetected UWL were greater in patients < 65 years old, with NSCLC, with obesity and who were White. In the 213 patients with recognized UWL, the documentation of UWL occurred approximately 7 months after their initial weight loss. The magnitude of weight loss was associated with cancer stage at cancer diagnosis ( p < 0.0001). Patients who experienced ≄ 7.5% UWL pre‐cancer diagnosis had a median cancer stage of 3 whereas patients who experienced < 7.5% UWL had a median cancer stage of 2 at cancer diagnosis ( p < 0.0001). Relative to patients with ≄ 7.5% weight loss, the < 7.5% weight loss group had 73.7% more patients with Stage 1 disease ( p < 0.0001) and 32.5% fewer patients with Stage 4 disease ( p = 0.0006) resulting in median cancer stage increasing from Stages 2 to 3. Conclusions: UWL was missed in 43% of cancer cachexia patients despite 8.6% ± 0.3% body weight loss prior to cancer diagnosis. When recognized, documentation of UWL did not occur until 7 months after weight loss initiation. A greater magnitude of UWL was associated with more advanced disease at cancer diagnosis. Recognition and timely diagnosis of UWL will increase the percentage of patients with curable, early‐stage disease.


  • Open Access

    Cancer Cachexia in STK11/LKB1 -mutated NSCLC is Dependent on Tumor-secreted GDF15

    byĀ Jinhai Yu, Tong Guo, Arun Gupta, Ernesto M. Llano, Naureen Wajahat, Sean Slater, Qing Deng, Esra A. Akbay, John M. Shelton, Bret M. Evers, et al.

    Cachexia is a wasting syndrome comprised of adipose, muscle, and weight loss observed in cancer patients. Tumor loss-of-function mutations in STK11/LKB1 , a regulator of the energy sensor AMP-activated protein kinase, induce cancer cachexia (CC) in preclinical models and are associated with cancer-related weight loss in NSCLC patients. Here we characterized the relevance of the NSCLC-associated cachexia factor growth differentiation factor 15 (GDF15) in several patient-derived and genetically engineered STK11/LKB1 -mutant NSCLC cachexia lines. Both tumor mRNA expression and serum concentrations of tumor-derived GDF15 were significantly elevated in multiple mice transplanted with patient-derived STK11/LKB1 -mutated NSCLC lines. GDF15 neutralizing antibody administered to mice transplanted with patient- or mouse-derived STK11/LKB1 -mutated NSCLC lines suppressed cachexia-associated adipose loss, muscle atrophy, and changes in body weight. The silencing of GDF15 in multiple human NSCLC lines was also sufficient to eliminate in vivo circulating GDF15 levels and abrogate cachexia induction, suggesting that tumor and not host tissues represent a key source of GDF15 production in these cancer models. Finally, reconstitution of wild-type STK11/LKB1 in a human STK11/LKB1 loss-of-function NSCLC line that normally induces cachexia in vivo correlated with the absence of tumor-secreted GDF15 and rescue from the cachexia phenotype. The current data provide evidence for tumor-secreted GDF15 as a conduit and a therapeutic target through which NSCLCs with STK11/LKB1 loss-of-function mutations promote cachexia-associated wasting.


  • Impact of Pretreatment Weight Loss on Radiotherapy Utilization and Clinical Outcomes in Non–Small Cell Lung Cancer

    byĀ Christian M. Alvarez, Maureen Aliru, Bhavani S. Gannavarapu, Tidie Song, Linda Anne Gilmore, Santiago Olaechea, Daniel R. Md Gomez, Chul Ahn, Rodney E. Infante, Puneeth Iyengar

    Background: Cancer cachexia is a syndrome of unintentional weight loss resulting in progressive functional impairment. Knowledge of radiation therapy utilization in patients with cancer cachexia is limited. We evaluated the use of curative and palliative-intent radiation for the management of patients with non–small cell lung cancer (NSCLC) with cachexia to determine whether tumor-directed therapy affected cachexia-associated outcomes. Methods: Using an Institutional Tumor Registry, we evaluated all patients with stages of NSCLC treated at a tertiary care system from 2006 to 2013. We adopted the international consensus definition for cachexia, with staging designated by the registry and positron emission tomography. Radiotherapy delivery and intent were retrospectively assessed. Results: In total, 1330 patients with NSCLC were analyzed. Curative-intent radiotherapy was utilized equally between patients with cachexia and non-cachexia with stages I to III NSCLC. Conversely, significantly more patients with stage IV disease and cachexia received palliative radiotherapy versus those without (74% vs 63%, P = 0.006). Cachexia-associated survival was unchanged irrespective of tumor-directed radiation therapy with curative or palliative intent. In fact, pretreatment cachexia was associated with reduced survival for patients with stage III NSCLC receiving curative-intent radiotherapy (median survival = 23.9 vs 15.0 mo, P = 0.009). Finally, multivariate analysis identified pretreatment cachexia as an independent variable associated with worsened survival (hazard ratio = 1.31, CI: 1.14,1.52). Conclusion: Patients with advanced NSCLC with cachexia received more palliative-intent radiation than those without weight loss. Tumor-directed therapy in either a curative or palliative approach failed to alter cachexia patient survival across all stages of the disease. These findings offer critical information on the appropriate utilization of radiation in the management of patients with NSCLC with cachexia.


  • Open Access

    Tumor loss-of-function mutations in STK11/LKB1 induce cachexia

    byĀ Puneeth Iyengar, Aakash Y. Gandhi, Jorge Granados, Tong Guo, Arun Gupta, Jinhai Yu, Ernesto M. Llano, Faya Zhang, Ang Gao, Asha Kandathil, et al.

    Cancer cachexia (CC), a wasting syndrome of muscle and adipose tissue resulting in weight loss, is observed in 50% of patients with solid tumors. Management of CC is limited by the absence of biomarkers and knowledge of molecules that drive its phenotype. To identify such molecules, we injected 54 human non–small cell lung cancer (NSCLC) lines into immunodeficient mice, 17 of which produced an unambiguous phenotype of cachexia or non-cachexia. Whole-exome sequencing revealed that 8 of 10 cachexia lines, but none of the non-cachexia lines, possessed mutations in serine/threonine kinase 11 ( STK11/LKB1 ), a regulator of nutrient sensor AMPK. Silencing of STK11/LKB1 in human NSCLC and murine colorectal carcinoma lines conferred a cachexia phenotype after cell transplantation into immunodeficient (human NSCLC) and immunocompetent (murine colorectal carcinoma) models. This host wasting was associated with an alteration in the immune cell repertoire of the tumor microenvironments that led to increases in local mRNA expression and serum levels of CC-associated cytokines. Mutational analysis of circulating tumor DNA from patients with NSCLC identified 89% concordance between STK11/LKB1 mutations and weight loss at cancer diagnosis. The current data provide evidence that tumor STK11/LKB1 loss of function is a driver of CC, simultaneously serving as a genetic biomarker for this wasting syndrome.


  • Open Access

    Racial, Ethnic, and Socioeconomic Characteristics Independently Predict for Cachexia Risk and Associated Survival Outcomes in Stage IV NSCLC: A Brief Report

    byĀ Santiago Olaechea, Alison Liu, Brandon Sarver, Linda Anne Gilmore, Christian Alvarez, Kayvon Yazdanbakhsh, Rodney Infante, Puneeth Iyengar


  • Open Access

    A preponderance of gastrointestinal cancer patients transition into cachexia syndrome

    byĀ Linda Anne Gilmore, Santiago Olaechea, Brian W. Gilmore, Bhavani S. Gannavarapu, Christian M. Alvarez, Chul Ahn, Puneeth Iyengar, Rodney E. Infante

    Background: Cancer cachexia is frequently documented by self‐reported, single time‐point weight histories. This approach lacks the granularity needed to fully elucidate the progression of cachexia syndrome. This study aimed to longitudinally assess body weight changes pre‐ and post‐cancer diagnosis in gastrointestinal (GI) cancer patients.Methods: Body weights and relevant clinical data recorded in the electronic health record 12 months pre‐ and post‐GI cancer (colorectal, gastroesophageal, hepatobiliary and pancreatic) diagnosis were extracted. Weight loss was categorized by the International Consensus Definition for cachexia.Results: A total of 879 patients were included in the final cohort including patients diagnosed with colorectal (n = 317), hepatocellular (n = 185), biliary (n = 72), pancreatic (n = 186) or gastroesophageal (n = 119) cancer. Stage of disease was equally distributed. Patients without cachexia at diagnosis (n = 608) remained weight stable during the 12 months pre‐diagnosis (+0.5 ± 0.5% body weight; P = 0.99). Patients with cachexia at diagnosis (n = 271) remained weight stable 6 to 12 months prior to diagnosis (+0.4 ± 0.8%; P > 0.9999) and lost 8.7 ± 0.6% (P < 0.0001) within the 6 months pre‐diagnosis. Patients without cachexia at diagnosis lost more weight post‐diagnosis (6.3 ± 0.6%) than patients with cachexia at diagnosis (4.7 ± 1.0%; P = 0.01). Pre‐diagnosis weight trajectories did not differ between primary malignancies or stage of disease in patients without or with cachexia at diagnosis (all P ≄ 0.05). Post‐diagnosis weight trajectories did differ by primary malignancy (P ≤ 0.0002) and stage (P < 0.0001). In both patients without and with cachexia at diagnosis, colorectal patients lost the least amount of weight post‐diagnosis and gastroesophageal patients lost the most amount of weight post‐diagnosis. Stage 4 patients without or with cachexia at diagnosis lost the most weight post‐diagnosis (P ≤ 0.0003). Regardless of cachexia status at diagnosis, patients lost more weight when treated with systemic therapy (7.1 ± 0.7%; P < 0.0001; n = 419) or radiation therapy (8.4 ± 1.4%; P = 0.02; n = 116) compared to those who did not. Patients who did not have surgery lost more weight post‐diagnosis (7.6 ± 1.1%; P < 0.0001; n = 355) compared to those who did have surgery. By 12 months post‐diagnosis, 83% of the surviving GI cancer patients in this cohort had transitioned into cachexia syndrome.Conclusions: Significant weight loss in patients with GI cancer cachexia at diagnosis initiates at least 6 months prior to diagnosis, and most patients will transition into cachexia syndrome post‐diagnosis, regardless of pre‐diagnosis weight change and stage of disease. These findings punctuate the importance of weight surveillance in cancer detection and earlier palliative interventions post‐diagnosis in the GI cancer patient population.


  • Open Access

    Primary Tumor Fluorine‐18 Fluorodeoxydglucose (18F‐FDG) Is Associated With Cancer-Associated Weight Loss in Non-Small Cell Lung Cancer (NSCLC) and Portends Worse Survival

    byĀ Santiago Olaechea, Bhavani S. Gannavarapu, Christian Alvarez, Anne Gilmore, Brandon Sarver, Donglu Xie, Rodney Infante, Puneeth Iyengar

    Aim: To investigate the diagnostic potential of and associations between tumor 18F‐FDG uptake on PET imaging and cancer-associated weight loss.Methods: 774 non-small cell lung cancer (NSCLC) patients with pre-treatment PET evaluated between 2006 and 2014 were identified. Using the international validated definition of cachexia, the presence of clinically significant pretreatment cancer-associated weight loss (WL) was retrospectively determined. Maximum Standardized Uptake Value (SUVMax) of 18F‐FDG was recorded and dichotomized based on 3 experimental cutpoints for survival analyses. Each SUVMax cutpoint prioritized either survival differences, total cohort comparison sample sizes, or sample size by stage. Patient outcomes and associations between SUVMax and cancer-associated weight loss were assessed by multivariate, categorical, and survival analyses.Results: Patients were found to have an increased likelihood of having WL at diagnosis associated with increasing primary tumor SUVMax after controlling for potentially confounding patient and tumor characteristics on multivariate logistic regression (OR 1.038; 95% CI: 1.012, 1.064; P=0.0037). After stratifying the cohort by WL and dichotomized SUVMax, both factors were found to be relevant in predicting survival outcomes when the alternative variable was constant. Of note, the most striking survival differences contributed by WL status occurred in high SUVMax groups, where the presence of WL predicted a median survival time detriment of up to 10 months, significant regardless of cutpoint determination method applied to categorize high SUVMax patients. SUVMax classification was found to be most consistently relevant in both WL and no WL groups.Conclusions: The significant positive association between significant pretreatment cancer-associated weight loss and primary tumor SUVMax underscores increased glucose uptake as a component of catabolic tumor phenotypes. This substantiates 18F‐FDG PET analysis as a prospective tool for assessment of cancer-associated weight loss and corresponding survival outcomes. Furthermore, the survival differences observed between WL groups across multiple SUVMax classifications supports the importance of weight loss monitoring in oncologic workups. Weight loss in the setting of NSCLCs with higher metabolic activity as determined by 18F‐FDG PET signal should encourage more aggressive and earlier palliative care interventions.